Medrol (Methylprednisolone) is a potent anti-inflammatory steroid. with a greater anti-inflammatory potency than prednisolone or hydrocortisone. Methylprednisolone is indicated for endocrine disorders, rheumatic disorders (including rheumatoid arthritis) and some allergies. The active ingredient in this drug works by acting within cells to prevent the release of certain chemicals that are important in the immune system.
These chemicals are normally involved in producing immune and allergic responses, resulting in inflammation. By decreasing the release of these chemicals in a particular area, inflammation is reduced. This can help control a wide number of disease states, characterised by excessive inflammation. They include severe allergic reactions, inflammation of the lungs in asthma and inflammation of the joints in arthritis.
The initial dosage should be maintained or adjusted until a satisfactory response is noted. If, after a reasonable period of time, there is a lack of satisfactory clinical response, it should be discontinued and the patient transferred to other appropriate therapy. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
- Difficulty in sleeping (insomnia)
- Thinning of the skin
- Increased pressure inside the eye (glaucoma)
- Weight gain
- Irregular menstrual cycle
- Thinning of the bones (osteoporosis)
- Ulceration of the stomach or intestine
- Increased susceptibility to infections
- Increased risk of fractures of the bones
- Increased hair growth (hirsutism)
- High blood pressure (hypertension)
- Supression of growth in children and adolescents
- Indigestion (dyspepsia)